Emerging drugs for treating the acute respiratory distress syndrome

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Introduction: The acute respiratory distress syndrome (ARDS) is a common and catastrophic condition, with a high mortality rate and economic burden on society. Despite 50 years of study, there is no specific pharmacological therapy for ARDS.

Areas covered: This review outlines the definitions, epidemiology, risk factors and pathophysiology of ARDS. The priority of developing a clinically-relevant model for ARDS to test pre-clinical candidates is discussed, together with the limitations of current models. The scientific rationale of emerging therapeutic candidates is outlined in the setting of the biological mechanisms implicated in the complex pathogenesis of ARDS. Emerging therapies, currently in clinical trials, are discussed, including the pre-clinical basis for their use and the expected timeline to trial completion.

Expert opinion: We highlight the necessity of improving pre-clinical models of ARDS and the design of clinical trials for the development of novel pharmacological therapies. We reflect on the most promising emerging strategies and their potential role in ARDS management.
Original languageEnglish
Pages (from-to)29-41
Number of pages13
JournalExpert opinion on emerging drugs
Volume24
Issue number1
DOIs
Publication statusPublished - 18 Mar 2019

Fingerprint

Adult Respiratory Distress Syndrome
Pharmaceutical Preparations
Clinical Trials
Pharmacology
Expert Testimony
Therapeutics
Epidemiology
Economics
Mortality

Keywords

  • Animals
  • Clinical Trials as Topic/methods
  • Cost of Illness
  • Drug Development/methods
  • Drug Evaluation, Preclinical/methods
  • Humans
  • Research Design
  • Respiratory Distress Syndrome, Adult/drug therapy
  • Risk Factors

Cite this

@article{3791b7aefe7947b2b46a7f632ad0dbc3,
title = "Emerging drugs for treating the acute respiratory distress syndrome",
abstract = "Introduction: The acute respiratory distress syndrome (ARDS) is a common and catastrophic condition, with a high mortality rate and economic burden on society. Despite 50 years of study, there is no specific pharmacological therapy for ARDS.Areas covered: This review outlines the definitions, epidemiology, risk factors and pathophysiology of ARDS. The priority of developing a clinically-relevant model for ARDS to test pre-clinical candidates is discussed, together with the limitations of current models. The scientific rationale of emerging therapeutic candidates is outlined in the setting of the biological mechanisms implicated in the complex pathogenesis of ARDS. Emerging therapies, currently in clinical trials, are discussed, including the pre-clinical basis for their use and the expected timeline to trial completion.Expert opinion: We highlight the necessity of improving pre-clinical models of ARDS and the design of clinical trials for the development of novel pharmacological therapies. We reflect on the most promising emerging strategies and their potential role in ARDS management.",
keywords = "Animals, Clinical Trials as Topic/methods, Cost of Illness, Drug Development/methods, Drug Evaluation, Preclinical/methods, Humans, Research Design, Respiratory Distress Syndrome, Adult/drug therapy, Risk Factors",
author = "Shaw, {Timothy D} and McAuley, {Daniel F} and O'Kane, {Cecilia M}",
year = "2019",
month = "3",
day = "18",
doi = "10.1080/14728214.2019.1591369",
language = "English",
volume = "24",
pages = "29--41",
journal = "Expert opinion on emerging drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "1",

}

Emerging drugs for treating the acute respiratory distress syndrome. / Shaw, Timothy D; McAuley, Daniel F; O'Kane, Cecilia M.

In: Expert opinion on emerging drugs, Vol. 24, No. 1, 18.03.2019, p. 29-41.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Emerging drugs for treating the acute respiratory distress syndrome

AU - Shaw, Timothy D

AU - McAuley, Daniel F

AU - O'Kane, Cecilia M

PY - 2019/3/18

Y1 - 2019/3/18

N2 - Introduction: The acute respiratory distress syndrome (ARDS) is a common and catastrophic condition, with a high mortality rate and economic burden on society. Despite 50 years of study, there is no specific pharmacological therapy for ARDS.Areas covered: This review outlines the definitions, epidemiology, risk factors and pathophysiology of ARDS. The priority of developing a clinically-relevant model for ARDS to test pre-clinical candidates is discussed, together with the limitations of current models. The scientific rationale of emerging therapeutic candidates is outlined in the setting of the biological mechanisms implicated in the complex pathogenesis of ARDS. Emerging therapies, currently in clinical trials, are discussed, including the pre-clinical basis for their use and the expected timeline to trial completion.Expert opinion: We highlight the necessity of improving pre-clinical models of ARDS and the design of clinical trials for the development of novel pharmacological therapies. We reflect on the most promising emerging strategies and their potential role in ARDS management.

AB - Introduction: The acute respiratory distress syndrome (ARDS) is a common and catastrophic condition, with a high mortality rate and economic burden on society. Despite 50 years of study, there is no specific pharmacological therapy for ARDS.Areas covered: This review outlines the definitions, epidemiology, risk factors and pathophysiology of ARDS. The priority of developing a clinically-relevant model for ARDS to test pre-clinical candidates is discussed, together with the limitations of current models. The scientific rationale of emerging therapeutic candidates is outlined in the setting of the biological mechanisms implicated in the complex pathogenesis of ARDS. Emerging therapies, currently in clinical trials, are discussed, including the pre-clinical basis for their use and the expected timeline to trial completion.Expert opinion: We highlight the necessity of improving pre-clinical models of ARDS and the design of clinical trials for the development of novel pharmacological therapies. We reflect on the most promising emerging strategies and their potential role in ARDS management.

KW - Animals

KW - Clinical Trials as Topic/methods

KW - Cost of Illness

KW - Drug Development/methods

KW - Drug Evaluation, Preclinical/methods

KW - Humans

KW - Research Design

KW - Respiratory Distress Syndrome, Adult/drug therapy

KW - Risk Factors

U2 - 10.1080/14728214.2019.1591369

DO - 10.1080/14728214.2019.1591369

M3 - Review article

C2 - 30841764

VL - 24

SP - 29

EP - 41

JO - Expert opinion on emerging drugs

JF - Expert opinion on emerging drugs

SN - 1472-8214

IS - 1

ER -